Mpox doesn’t always cause illness, yet many patients have long-term effects, studies suggest
January 20, 2026
New research suggests mpox is both quieter and more persistent than surveillance systems assume. Evidence published in Nature Communications points to silent circulation in Nigeria, where immune markers reveal recent mpox exposure without recognized illness. At the same time, findings in Annals of Internal Medicine show that more than half of patients experience lasting physical or psychosocial effects long after diagnosis. Together, these studies challenge symptom-based surveillance and short-term care models. Mpox control must account for unseen transmission and long-term consequences, not just reported cases.
Two complementary studies underscore a growing reality about mpox. The virus can circulate unnoticed, and when illness does occur, its effects often persist long after acute infection. Research published in Nature Communications reveals evidence of silent mpox exposure in Nigeria, while a parallel analysis in Annals of Internal Medicine documents long-term sequelae among patients more than a year after diagnosis.
In Nigeria, investigators from the University of Cambridge and the Institute of Human Virology Nigeria identified immune responses consistent with recent mpox exposure in individuals who reported no symptoms and had no known diagnosis. These immune footprints suggest that mpox does not always present with classical rash or systemic illness. Instead, partial population immunity, shaped by historical smallpox vaccination, may allow low-level transmission that evades routine clinical surveillance. Genomic analyses reinforced this picture, showing slow epidemic growth and frequent transmission dead ends rather than explosive spread.
The implications are significant. Surveillance systems that rely solely on reported cases may underestimate mpox circulation, particularly in endemic settings. Serologic monitoring could provide a clearer picture of exposure patterns and help guide targeted vaccination strategies.
At the same time, findings from the Life After Mpox Study complicate assumptions about recovery. More than half of individuals previously infected with clade II mpox reported persistent physical or psychosocial effects up to 18 months later. Scarring was common, and a notable minority experienced ongoing anorectal or urinary dysfunction. Social and psychological impacts, including stigma and reduced quality of life, were also frequent.
Taken together, these studies argue for a broader mpox framework. Public health responses must move beyond counting cases to detecting hidden transmission and supporting long-term recovery. Mpox is not only an acute outbreak to contain. It is a condition with enduring and often invisible consequences that demand sustained attention.